Whole-Genome Study Shows IGF1R Inhibitors May Help Some Osteosarcoma Patients

04:54 EDT 23 Jun 2017 | Genetic Engineering News

Researchers report in Nature Communications (“ Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma ”) that a genetic sequencing study has revealed that some patients with osteosarcoma could be helped by an existing drug. The team, from the Wellcome Trust Sanger Institute, University College London Cancer Institute, and the Royal National Orthopedic Hospital NHS Trust, that 10% of patients with a genetic mutation in particular growth-factor-signaling genes may benefit from IGF1R inhibitors. The results, the scientists say, suggest a re-trial of IGF1R inhibitors for the subset of patients with osteosarcoma who are likely to respond based on their genetic profile. The current treatment for osteosarcoma is chemotherapy followed by surgery, where the bone tumors are removed. There has not been a new treatment for osteosarcoma in almost 40 years. In the study, investigators analyzed the genome of 112 childhood and ...

Original Article: Whole-Genome Study Shows IGF1R Inhibitors May Help Some Osteosarcoma Patients


More From BioPortfolio on "Whole-Genome Study Shows IGF1R Inhibitors May Help Some Osteosarcoma Patients"

Quick Search


Relevant Topics

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...